세계 타액누증 치료 시장 : 지역별 점유율, 동향, 성장 기회 분석 - 의료요법별, 최종 사용자별

According to our latest study on "Sialorrhea Treatment Market Forecast to 2030 - Global Analysis - by Medical Therapy and End User," the market was valued at US$ 0.695 billion in 2022 and is expected to reach US$ 1.042 billion by 2030; it is estimated to record a CAGR of 5.2% from 2022 to 2030.

The market growth is attributed to the increasing prevalence of neurodegenerative disorders and the availability of various treatment options for sialorrhea. Moreover, rising research and development (R&D) and new drug approvals will likely fuel the sialorrhea treatment market growth in the coming years. However, challenges related to sialorrhea treatment restrain the market growth.

Treatments for sialorrhea include behavioral and lifestyle counseling, medication, surgery, and radiation. Nonpharmacological therapies include advice on posture, controlling swallowing, managing cough, dietary adjustments, eating and drinking procedures, and behavioral modification. Nevertheless, these conservative measures might not work for individuals with neurological problems that worsen over time. Many drugs that have been used to treat sialorrhea also have anticholinergic properties that have been utilized to control hypersalivation. Amitriptyline, procyclidine, and rihexyphenidyl are a few of these. Most medications have co-morbidities (such as discomfort or trouble sleeping) and hypersalivation, which makes them potentially helpful in some situations. Therefore, the availability of various treatments for sialorrhea is expected to boost market growth in the coming years.

However, diagnosis and treatment of chronic sialorrhea are delayed due to patient and healthcare professional ignorance about the condition. This is anticipated to be the main obstacle impeding the market expansion for chronic sialorrhea treatments. Furthermore, it is anticipated that healthcare professionals-including specialists and primary care doctors-will know very little about persistent sialorrhea as a separate illness.

The report segments the sialorrhea treatment market as follows:

The sialorrhea treatment market is bifurcated based on medical therapy and end users. The market is segmented by medical treatment into pharmacologic therapy, radiotherapy, and others. The sialorrhea treatment market, by end-user, is segmented into hospitals, specialty clinics, home care settings, and others. The sialorrhea treatment market, based on geography, is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America)

Medical Therapy-Based Insights

Based on medical therapy, the sialorrhea treatment market is segmented into pharmacologic therapy, radiotherapy, and others. In 2022, the pharmacologic therapy segment held the largest market share. Also, the segment is expected to record the highest CAGR from 2022 to 2030. Vaccines provide active acquired immunity against particular infectious diseases. In multiple independent clinical trials, pharmacological treatments such as benztropine, glycopyrrolate, scopolamine, and botulinum toxins have been demonstrated to be effective in managing sialorrhea. Medications are delivered orally or parenterally. Botulinum toxin is injected into the salivary gland guided by anatomical external palpation or ultrasonography.

End User-Based Insights

The sialorrhea treatment market, by end-user, is segmented into hospitals, specialty clinics, home care settings, and others. The hospitals segment held the largest market share in 2022 and is anticipated to record the highest CAGR during 2022-2030. The treatment for sialorrhea is done in hospitals through appropriate treatment and motor therapy, with the help of highly experienced interdisciplinary medical specialists, including physiotherapists and neurology specialists.

A few of the major primary and secondary sources referred to while preparing the report on the sialorrhea treatment market are the World Health Organization (WHO) and the Parkinson's Foundation, among others.

Table Of Contents

1. Introduction

• 1.1 Scope of the Study
• 1.2 Market Definition, Assumptions and Limitations
• 1.3 Market Segmentation

2. Executive Summary

• 2.1 Key Insights
• 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Sialorrhea Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis
• 4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. Sialorrhea Market - Key Market Dynamics

• 5.1 Key Market Drivers
• 5.2 Key Market Restraints
• 5.3 Key Market Opportunities
• 5.4 Future Trends
• 5.5 Impact Analysis of Drivers and Restraints

6. Sialorrhea Market - Global Market Analysis

• 6.1 Sialorrhea - Global Market Overview
• 6.2 Sialorrhea - Global Market and Forecast to 2030

7. Sialorrhea Market - Revenue Analysis (USD Million) - By Medical Therapy, 2020-2030

• 7.1 Overview
• 7.2 Pharmacologic Therapy
  • 7.2.1 Anticholinergic
  • 7.2.2 Botulinum Toxins
• 7.3 Radiotherapy
• 7.4 Others

8. Sialorrhea Market - Revenue Analysis (USD Million) - By End User, 2020-2030

• 8.1 Overview
• 8.2 Hospitals
• 8.3 Specialty Clinics
• 8.4 Homecare Settings
• 8.5 Others

9. Sialorrhea Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

• 9.1 North America
  • 9.1.1 North America Sialorrhea Market Overview
  • 9.1.2 North America Sialorrhea Market Revenue and Forecasts to 2030
  • 9.1.3 North America Sialorrhea Market Revenue and Forecasts and Analysis - By Medical Therapy
  • 9.1.4 North America Sialorrhea Market Revenue and Forecasts and Analysis - By End User
  • 9.1.5 North America Sialorrhea Market Revenue and Forecasts and Analysis - By Countries
    • 9.1.5.1 United States Sialorrhea Market
      • 9.1.5.1.1 United States Sialorrhea Market, by Medical Therapy
      • 9.1.5.1.2 United States Sialorrhea Market, by End User
    • 9.1.5.2 Canada Sialorrhea Market
      • 9.1.5.2.1 Canada Sialorrhea Market, by Medical Therapy
      • 9.1.5.2.2 Canada Sialorrhea Market, by End User
    • 9.1.5.3 Mexico Sialorrhea Market
      • 9.1.5.3.1 Mexico Sialorrhea Market, by Medical Therapy
      • 9.1.5.3.2 Mexico Sialorrhea Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

• 9.2 Europe
  • 9.2.1 Germany
  • 9.2.2 France
  • 9.2.3 Italy
  • 9.2.4 Spain
  • 9.2.5 United Kingdom
  • 9.2.6 Rest of Europe
• 9.3 Asia-Pacific
  • 9.3.1 Australia
  • 9.3.2 China
  • 9.3.3 India
  • 9.3.4 Japan
  • 9.3.5 South Korea
  • 9.3.6 Rest of Asia-Pacific
• 9.4 Middle East and Africa
  • 9.4.1 South Africa
  • 9.4.2 Saudi Arabia
  • 9.4.3 U.A.E
  • 9.4.4 Rest of Middle East and Africa
• 9.5 South and Central America
  • 9.5.1 Brazil
  • 9.5.2 Argentina
  • 9.5.3 Rest of South and Central America

10. Industry Landscape

• 10.1 Mergers and Acquisitions
• 10.2 Agreements, Collaborations, Joint Ventures
• 10.3 New Product Launches
• 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

• 11.1 Heat Map Analysis by Key Players
• 11.2 Company Positioning and Concentration

12. Sialorrhea Market - Key Company Profiles

• 12.1 Supernus Pharmaceuticals, Inc.
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies

• 12.2 Proveca Ltd
• 12.3 Merz Pharmaceuticals, LLC.
• 12.4 Allergan
• 12.5 GlaxoSmithKline
• 12.6 Shionogi Inc.
• 12.7 BAYER INC
• 12.8 Novartis Pharmaceuticals Corporation
• 12.9 Nobelpharma Co., Ltd.
• 12.10 Bristol-Myers Squibb Company

13. Appendix

• 13.1 Glossary
• 13.2 About The Insight Partners
• 13.3 Market Intelligence Cloud